0001209191-19-052864.txt : 20191009
0001209191-19-052864.hdr.sgml : 20191009
20191009200236
ACCESSION NUMBER: 0001209191-19-052864
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191007
FILED AS OF DATE: 20191009
DATE AS OF CHANGE: 20191009
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kennedy Joseph T
CENTRAL INDEX KEY: 0001408920
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-21392
FILM NUMBER: 191145150
MAIL ADDRESS:
STREET 1: C/O TRANSCEPT PHARMACEUTICALS, INC.
STREET 2: 1003 W. CUTTING BLVD., SUITE 110
CITY: POINT RICHMOND
STATE: CA
ZIP: 94804
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMARIN CORP PLC\UK
CENTRAL INDEX KEY: 0000897448
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: FIRST FLOOR, BLOCK 3, THE OVAL,
STREET 2: SHELBOURNE ROAD, BALLSBRIDGE
CITY: DUBLIN
STATE: L2
ZIP: 00000
BUSINESS PHONE: 353 1 6699 020
MAIL ADDRESS:
STREET 1: FIRST FLOOR, BLOCK 3, THE OVAL,
STREET 2: SHELBOURNE ROAD, BALLSBRIDGE
CITY: DUBLIN
STATE: L2
ZIP: 00000
FORMER COMPANY:
FORMER CONFORMED NAME: AMARIN PHARMACEUTICALS PLC
DATE OF NAME CHANGE: 20000201
FORMER COMPANY:
FORMER CONFORMED NAME: ETHICAL HOLDINGS PLC
DATE OF NAME CHANGE: 19930322
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-10-07
0
0000897448
AMARIN CORP PLC\UK
AMRN
0001408920
Kennedy Joseph T
C/O AMARIN PHARMA, INC.
440 US HIGHWAY 22
BRIDGEWATER
NJ
08807
0
1
0
0
General Counsel
Ordinary Shares
2019-10-07
4
A
0
199500
A
230760
D
Ordinary Shares
2019-10-07
4
F
0
105037
14.37
D
125723
D
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
In January 2015, 399,000 restricted stock units (the "RSUs") were approved to be granted and, following the Annual General Meeting of Shareholders held in July 2015, were granted to the Reporting Person under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. The RSUs vested in two equal installments based on the Issuer's satisfaction of certain performance criteria and continued employment of the Reporting Person as provided in the Restricted Stock Unit Award Agreement between the Issuer and the Reporting Person. Vesting of the second and final installment was achieved based on a predetermined performance-based formula tied to company cash flow as determined by the Remuneration Committee of the Board of Directors, resulting in the vesting of 199,500 RSUs.
Not applicable.
Please see the section titled "Remarks" below for additional information.
Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.
As of the date of this Form 4, the Reporting Person owns or holds the right to acquire an aggregate of 774,521 Ordinary Shares of the Issuer in the form of Ordinary Shares, stock options and Restricted Stock Units granted under the Plan, including but not limited to certain performance-based Restricted Stock Units that are earned only if product revenues reach pre-defined annual milestone levels and, in certain cases, then vest only if the recipient remains with the company for an extended period of time.
/s/ Joseph T. Kennedy
2019-10-09